trending Market Intelligence /marketintelligence/en/news-insights/trending/VpqpVltOd5YKifSvTvBf2A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Astellas Pharma closes $3B acquisition of Audentes Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Astellas Pharma closes $3B acquisition of Audentes Therapeutics

Japanese drugmaker Astellas Pharma Inc. completed the acquisition of San Francisco-based Audentes Therapeutics Inc. in a deal holding an equity value of about $3 billion.

Astellas said it completed a tender offer to acquire all the issued and outstanding shares of Audentes at $60 apiece through its subsidiary Asilomar Acquisition Corp. and has merged Audentes with the unit.

By the end of the tender offer period on Jan. 14, about 76.7% of Audentes' outstanding common stock was validly tendered.

Natalie Holles, who had been Audentes' president and COO, was appointed as its president and CEO, Astellas said in a Jan. 15 press release.

Astellas added that Audentes will operate as its unit and serve as a center of excellence for its newly created Genetic Regulation Primary Focus program for developing and commercializing AAV-based genetic drugs.

Tokyo-based Astellas noted the acquisition would strengthen the combined company's position in genetic medicines, which are based on Adeno-associated virus, or AAV. Astellas said earlier that the deal creates opportunities for additional gene therapy partnerships besides gaining Audentes' lead program AT132 to treat a rare neuromuscular disease called X-linked myotubular myopathy.

Holles said the company plans to submit a biologics license application for AT132 to the U.S. Food and Drug Administration later in 2020.

Morgan Stanley & Co. LLC, through its affiliate Mitsubishi UFJ Morgan Stanley Securities Co. Ltd., was the exclusive financial adviser, while Covington & Burling LLP acted as legal counsel to Astellas.

Centerview Partners LLC was the exclusive financial adviser, and Fenwick & West LLP acted as legal counsel to Audentes.